Autopsy report · NCT00313196

Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)

“Slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Actelion

Sponsor type

Industry

Conditions

Pulmonary Hypertension

Interventions

bosentan

Participants

12

Trials that died the same way

• EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study
  “too slow enrollment” (95% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.